UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14A
Proxy Statement
Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
Filed by the Registrant ☐
Filed by a party other than the Registrant ☒
Check the appropriate box:
| ☐ |
Preliminary Proxy Statement
|
| ☐ |
Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
|
| ☐ |
Definitive Proxy Statement
|
| ☒ |
Definitive Additional Materials
|
| ☐ |
Soliciting Material under § 240.14a-12
|
Amarin
Corporation plc
(Name of Registrant as Specified In Its Charter)
Sarissa Capital
Catapult Fund LLC
Sarissa Capital
Hawkeye Fund LP
ISP Fund
LP
Sarissa Capital
Offshore Master Fund LP
Sarissa Capital
Master Fund II LP
Sarissa Capital
Athena Fund Ltd
Atom Master
Fund LP
Sarissa Capital
Fund GP LP
Sarissa Capital
Fund GP LLC
Sarissa Capital
Offshore Fund GP LLC
Sarissa Capital
Management GP LLC
Sarissa Capital
Management LP
Alexander J.
Denner, Ph.D.
Patrice
Bonfiglio
Paul Cohen,
M.D.
Mark
DiPaolo
Keith L.
Horn
Odysseas
Kostas, M.D.
Louis Sterling
III
Diane E.
Sullivan
(Name of Person(s) Filing
Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☐ |
Fee paid previously with preliminary materials
|
| ☐ |
Fee computed on table in exhibit required by Item 25(b) per
Exchange Act Rules 14a-6(i)(1) and 0-11
|
This filing contains a press release issued on February 28,
2023 by Sarissa Capital.
SARISSA CAPITAL WINS PROXY CONTEST AGAINST AMARIN BY HUGE
LANDSLIDE
Sarissa honored to have received 100 million more votes than Amarin
board
Greenwich,
CT, February 28, 2023 – Sarissa Capital Management LP today issued
the following statement regarding Amarin Corporation plc (NASDAQ:
AMRN):
Amarin shareholders have sent a
loud and clear message repudiating the incumbent Amarin board.
Sarissa thanks fellow shareholders for their support in a
resounding victory against the Amarin board. Our estimate is that
up to nearly 80% of shareholder votes were in support of Sarissa.
As Amarin’s largest shareholder, we are grateful for the
opportunity to remake Amarin for the benefit of all
shareholders.
Vascepa, the foundation on which
Amarin is built, is a tremendous drug that is compelling for
patients and payors – a unique proposition for a drug. While there
is a lot of work to be done, we remain confident in our ability to
leverage Vascepa’s rare and highly beneficial profile to unlock
tremendous value for all shareholders.
LET’S GET TO
WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL
SHAREHOLDERS!
Additional
Information
Sarissa Capital Management LP
(“Sarissa Capital”), together with other participants, filed a
definitive proxy statement and an accompanying blue proxy card with
the SEC on January 31, 2023, in connection with the solicitation of
shareholders of Amarin Corporation plc (the “Company”) at the
general meeting of the Company for the election of Sarissa
Capital’s slate of highly-qualified nominees (the “General
Meeting”). Shareholders are advised to read the definitive proxy
statement and other relevant documents related to the General
Meeting as they contain important information.
The definitive proxy statement and
other relevant documents are available at no charge on the SEC’s
website at www.sec.gov and at www.freeamarin.com. The
definitive proxy statement and other relevant documents are also
available at no charge by directing a request to Sarissa Capital’s
proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New
York, New York 10005 (Shareholders can call toll-free: (800)
331-7024).
#FreeAmarin
|
Contact: |
Dayna Packes
Sarissa Capital Management LP
info@sarissacap.com
|